Vor Biopharma (VOR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Cell Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-15. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 59/100 (HIGH), 18.9 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 17.88% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)
- Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
- Vor Bio To Participate in Upcoming September Conferences
- Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next
- We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely
- Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0. — J Immunother Cancer 2026 Sep 21 PMID 42767771
- A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial. — Nat Med 2026 Sep PMID 42722888
- Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+). — Front Neurol 2026 PMID 42699831
- Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. — JAMA Neurol 2026 Sep 1 PMID 42507440
- Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial. — N Engl J Med 2026 May 14 PMID 42127391
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Vor Biopharma.
Full VOR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.